ADARx Pharmaceuticals Stock

adarx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $505MM

ADARx Pharmaceuticals is a company that specializes in genetic medicine designed to treat human diseases and ailments using mRNA transcripts. ADARx researches and develops its therapies through oligonucleotides delivery technology. The firm focuses on three main disease treatments: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for ADARx Pharmaceuticals, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

ADARx Pharmaceuticals Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

ADARx Pharmaceuticals Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/09/2023 Series C $200MM $xx.xx $827.77MM Ascenta Capital, Bain Capital Life Sciences, Blackrock, Commodore Capital, Cormorant Asset Management, Hbm Healthcare Investments, Invus, Lilly Asia Ventures, Marshall Wace, Orbimed Advisors, Redmile Group, Sr One Capital Management, Tcgx, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital
Price per Share
$xx.xx
Shares Outstanding
24,038,463
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ascenta Capital, Bain Capital Life Sciences, Blackrock, Commodore Capital, Cormorant Asset Management, Hbm Healthcare Investments, Invus, Lilly Asia Ventures, Marshall Wace, Orbimed Advisors, Redmile Group, Sr One Capital Management, Tcgx, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital
01/20/2023 Series B-1 $46MM $xx.xx $484.32MM Ascenta Capital, Lilly Asia Ventures, Orbimed Advisors, Sirona Capital, Sr One Capital Management
Price per Share
$xx.xx
Shares Outstanding
6,913,353
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ascenta Capital, Lilly Asia Ventures, Orbimed Advisors, Sirona Capital, Sr One Capital Management
09/08/2021 Series B $75MM $xx.xx $361.97MM Lilly Asia Ventures, Orbimed Advisors, Sirona Capital, Sr One Capital Management
Price per Share
$xx.xx
Shares Outstanding
14,653,302
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Lilly Asia Ventures, Orbimed Advisors, Sirona Capital, Sr One Capital Management
05/14/2021 Series A $31.5MM $xx.xx $52.5MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
31,315,236
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

ADARx Pharmaceuticals Investors Also Invested in These Private Companies

Venrock Healthcare Capital Partners
Sirona Capital

Leadership & Board

Leadership

Zhen Li Ph.D
Co-Founder, Chief Executive Officer & President
Christopher Prentiss
Chief Financial Officer
Robert MacLeod Ph.D
Chief Scientific Officer
Rui Zhu Ph.D
Co-Founder & Vice President, Research and Development

Board

Chen-Ming Yu MD
TCG Crossover Management
Erez Chimovits
OrbiMed
Judith Li
Lilly Asia Ventures
Lorence Kim MD
Ascenta Capital
Ricky Sun Ph.D
Bain Capital Life Sciences
Simeon George MD
SR One Capital Management
Yuan Sun
Sirona Capital

ADARx Pharmaceuticals stock FAQs

plusminus

Can you buy ADARx Pharmaceuticals stock?

As ADARx Pharmaceuticals is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like ADARx Pharmaceuticals, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy ADARx Pharmaceuticals stock?

To invest in a private company like ADARx Pharmaceuticals through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell ADARx Pharmaceuticals stock?

Yes, you may sell the ADARx Pharmaceuticals stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell ADARx Pharmaceuticals stock?

If you hold private company shares of ADARx Pharmaceuticals – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your ADARx Pharmaceuticals on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is ADARx Pharmaceuticals a public company?

No, ADARx Pharmaceuticals is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is ADARx Pharmaceuticals’ stock price?

ADARx Pharmaceuticals is a privately held company and therefore does not have a public stock price. However, you may access ADARx Pharmaceuticals private market stock price with Forge Data.
plusminus

What is ADARx Pharmaceuticals’ stock ticker symbol?

ADARx Pharmaceuticals does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

ADARx Pharmaceuticals News and Media Highlights

Fresh off massive fundraising, ADARx preps 3rd clinical program and mulls IPO

2023 has been a banner year for San Diego-based siRNA biotech ADARx Pharmaceuticals, with two assets jumping to the clinic and $200 million brought in through one of the largest private financing rounds of the year. Next year could be even bigger, as ADARx collects early data on clinical programs that have caught the eye of investors and Big Pharmas. “The street has started to pay attention to us," CEO Zhen Li, Ph.D., told Fierce Biotech in an interview.

ADARx Pharmaceuticals Raises $200M in Series C Financing

ADARx Pharmaceuticals, Inc., a San Diego, CA-based clinical stage biotechnology company developing next generation RNA therapeutics, closed a $200m Series C financing. The round was led jointly by Bain Capital Life Sciences and TCGX and also included new investors Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates Inc., Venrock Healthcare Capital Partners, and Vivo Capital, as well as existing investors, Ascenta Capital, Lilly Asia Ventures, OrbiMed, and SR One Capital Management.

RNA biotech ADARx hauls in $200M, almost doubling 2 previous raises combined

Who says crossover rounds are dying? ADARx has raked in a $200 million series C, almost twice as much as the previous two joint series B rounds combined. The question now is, how quickly can the biotech's RNA pipeline be expanded? The new financing shared Wednesday will help ADARx advance two lead assets—ADX-324 and ADX-038—into the clinic, though more precise timing wasn’t disclosed. Since September 2021, the biotech had raised $121 from a series B and series B-1 round. The latter was announced in January, adding $46 million to ADARx’s bank.

ADARx Raises $75 Million to Advance Growing Pipeline

ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, today announced the completion of a $75 million Series B financing to advance its drug development pipeline. The Series B was co-led by SR One Capital Management and OrbiMed Advisors. Sirona Capital joined this financing as well as existing investors OrbiMed Advisors and Lilly Asia Ventures.
Browse Insights
Updated on: Dec 1, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.